- 专利标题： Fusion protein having enhanced in vivo activity of erythropoietin
-
申请号： US10230454申请日： 2002-08-29
-
公开(公告)号： US07098318B2公开(公告)日： 2006-08-29
- 发明人: Dong-Eok Lee , Myung-Suk Oh , Bo-Sup Chung , Ji-Sook Park , Ki-Wan Kim
- 申请人： Dong-Eok Lee , Myung-Suk Oh , Bo-Sup Chung , Ji-Sook Park , Ki-Wan Kim
- 申请人地址： KR
- 专利权人： Cheil Jedang Corporation
- 当前专利权人： Cheil Jedang Corporation
- 当前专利权人地址： KR
- 代理机构： Edwards Angell Palmer & Dodge LLP
- 代理商 Peter F. Corless; Christine C. O'Day
- 优先权： KR2001-74975 20011129
- 主分类号： C07K14/59
- IPC分类号： C07K14/59 ; C07H21/00 ; C12P21/06 ; A61K38/24
摘要：
The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.
公开/授权文献
信息查询
